Clinicians may safely use ranibizumab 0.5 mg in patients with bilateral age-related macular degeneration (AMD) as well as those with best-corrected visual acuity (BCVA) of less than 2/10, an Italian real-life study suggests.
A model based on simple birth characteristics may provide a new, more efficient method for predicting the need for retinopathy of prematurity treatment in infants, according to researchers.
A novel eyedrop formulation of dexamethasone was found to reduce swelling and improve vision in a Phase II trial of patients with diabetic macular oedema (DME).
Calcified nodules in the retina are associated with progression to late stages of age-related macular degeneration (AMD), researchers say.
Experimental treatments could slash the number of injections needed to successfully treat neovascular age-related macular degeneration (nAMD).
A dexamethasone implant improves visual acuity more than anti-vascular endothelial growth factor (VEGF) injections do in real-life studies in patients with diabetic macular oedema (DMO), researchers say.
Micoaneurysm turnover in the early stages of diabetic retinopathy predicts how much the disease will progress, according to researchers.
People with Alzheimer’s disease are more likely to have drusen in their peripheral retinas, as well as unusual vascular characteristics, researchers believe.
Two patients with macular degeneration regained reading vision after receiving stem cells implanted with a new technique, according to researchers.
A low dose of ranibizumab (Lucentis, Genentech/Roche) works well as a treatment for retinopathy of prematurity (ROP), researchers say.